Rocket Pharmaceuticals Inc. (RCKT) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

RCKT scores 28 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 3/20 (ROIC -35%; FCF yield 0%), Whale 13F Flow at 5/20 (institutional accumulation and options positioning), Insider Conviction at 5/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 8/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 7/20 (Altman Z 0.2; Piotroski F 3/9; Debt/Equity 0.5). The weakest pillar is the cash engine, consistent with the reported ROIC of -35% and zero FCF yield. For a prospective investor, the rating signals that the business is not currently generating cash returns on its capital, and the forensic metrics point to elevated balance-sheet risk. Any upside case would have to rest on events outside the reported cash-generation profile, since the rating assigns the lowest weight to near-term cash fundamentals.

Rocket Pharmaceuticals Inc. Is a NASDAQ-listed issuer classified in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. It operates with a market capitalization of $0.3B.

Operating and net losses persist across all three reported periods, with gross, operating, and net margins each at 0%. Per the market data, ROIC is -35%. The Altman Z-Score is 0.2, the Piotroski F-Score is 3/9, and Debt/Equity is 0.5. Reported cash declined from $163.6M in FY 2024 to $77.6M in FY 2025, while FCF remained negative in each period, so the source data indicates ongoing cash consumption rather than self-funding.

• 🐂 Primary Bull Case: Multiple firms including Goldman Sachs have issued upgrades or maintained ratings, and a credit facility of up to $150 Million has been secured. With Fundamental Cash Engine at 3/20 (ROIC -35.0%, FCF yield —) and Institutional Whale Flow at 5/20, sustained execution supports upside toward the top of the $2.16 – $5.45 52-week range.
• 🐻 Primary Bear Case: ROIC of -35%, zero FCF yield, Altman Z of 0.2, and Piotroski F of 3/9 signal severe cash-burn and balance-sheet risk. Investors must weigh current valuation against — operating margins and a 1.00 macro beta if sector demand softens.

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), RCKT carries a macro regime beta of 1.00 and gross margin of —.

• Key Question #1: What is the drawn amount, covenant structure, and repayment schedule of the Hercules Capital facility?
• Key Question #2: What are the clinical and regulatory milestones underlying the Jefferies price-target change and the Leerink and Goldman Sachs ratings?
• Key Question #3: What is the company's revenue model and does any product generate commercial sales?